Outlook Therapeutics (OTLK) announced that the National Institute for Health and Care Excellence, NICE, has recommended LYTENAVA, as an option ...

Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90 ...

An announcement from Outlook Therapeutics ( (OTLK) ) is now available.

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Fintel reports that on December 2, 2024, Chardan Capital downgraded their outlook for Outlook Therapeutics (NasdaqCM:OTLK) from Buy to Neutral. Analyst Price Forecast Suggests 1,865.37% Upside As of ...

Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for Outlook Therapeutics in a report issued ...

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...

On Wednesday, Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $1.7 which represents a decrease of $-3.19 or -65.24% from the prior close of $4.89. The stock opened at $0.98 and ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study evaluating ONS-5010 (Lytenava) to treat patients with wet age-related ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.